Home Protein Tyrosine Kinase VEGFR inhibitor Emvododstat (PTC299)

research use only

Emvododstat (PTC299) VEGFR inhibitor

Cat.No.E1078

Emvododstat (PTC299) is a post-transcriptional inhibitor of pathogenic VEGF and dihydroorotate dehydrogenase(DHODH), which inhibits VEGFA mRNA translation and abnormal cell proliferation. In HeLa cells, this compound inhibits hypoxia-induced VEGFA protein production with an EC50 of 1.64 nM.
Emvododstat (PTC299) VEGFR inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 467.34

Jump to

Quality Control

Batch: E107801 DMSO]93 mg/mL]false]Water]Insoluble]false]Ethanol]Insoluble]false Purity: 99.60%
  • Cited in Nature Medicine for its top-tier quality
  • COA
  • NMR
  • HPLC
  • SDS
  • Datasheet
99.60

Solubility

In vitro
Batch:

DMSO : 93 mg/mL (198.99 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 467.34 Formula

C25H20Cl2N2O3

 Storage (From the date of receipt) 3 years -20°C powder
CAS No. 1256565-36-2 -- Storage of Stock Solutions

Mechanism of Action

Targets/IC50/Ki
Dihydroorotate dehydrogenase
VEGFA
(in hypoxia-induced VEGFA protein inhibition assay of HeLa cells)
1.64 nM(EC50)
In vitro

Emvododstat (PTC299) inhibits hypoxia-induced VEGFA protein production in HeLa cells with an EC50 of 1.64 ± 0.83 nM. It is the most potent inhibitor with an IC50 of about 1 nM, over 10 to 1000-fold more potent than Brequinar, Vidofludimus or A77-1726 in leukemia cells. The decreased translation of VEGFA mRNA by this compound is linked to the inhibition of de novo pyrimidine nucleotide synthesis as exogenously added uridine, but not other nucleosides, can completely block the inhibition of VEGFA production by Emvododstat.
In vivo

In rats and dogs, Emvododstat (PTC299) has no adverse off‐target effects and no adverse effects on neurological or cardiopulmonary organ systems.
References
  • [4] https://pubmed.ncbi.nlm.nih.gov/27310330/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03761069 Terminated
Leukemia Myeloid Acute|AML
PTC Therapeutics
 October 29 2018 Phase 1
NCT00911248 Terminated
Neurofibromatosis 2
PTC Therapeutics|United States Department of Defense
 July 31 2009 Phase 2
NCT00704821 Terminated
Advanced Cancer
PTC Therapeutics
 July 3 2008 Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map